SCHEMBL2734265

SCHEMBL2734265

CCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OCCCCCCCCCCCCCCCC

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 2/20 0.83
LMNA P02545 2/20 0.83
ALDH1A1 P00352 2/20 0.83
PRKD3 O94806 1/20 0.83
PRKCG P05129 1/20 0.83
PRKCB P05771 1/20 0.83
PRKCA P17252 1/20 0.83
PRKCH P24723 1/20 0.83
PRKCI P41743 1/20 0.83
PRKCE Q02156 1/20 0.83
PRKCQ Q04759 1/20 0.83
PRKCZ Q05513 1/20 0.83
PRKCD Q05655 1/20 0.83
PRKD1 Q15139 1/20 0.83
MAPK1 P28482 1/20 0.83
SMN1; SMN2 Q16637 1/20 0.83
MEN1 O00255 1/20 0.83
GMNN O75496 1/20 0.83
BLM P54132 1/20 0.83
KMT2A Q03164 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10565337 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL15477735 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL10564175 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL2582886 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL1532761 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL2733343 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL10565746 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL417053 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL10602960 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG
SCHEMBL4320248 1.00 AKT1 (0.83) AKT1LMNAALDH1A1PRKD3PRKCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6613352-B2 Administration a low-rigidity liposomal formulation comprising anionic and neutral phospholipids, free of cholesterol and an active agent for preventing or diagnosis of a nonbacterial microbal infection in human UNIVERSITE DE MONTREAL (CA) 2003-09-02 US claimed
US-20010006660-A1 LOW-RIGIDITY LIPOSOMAL FORMULATION UNIVERSITE DE MONTREAL (CA) 2001-07-05 US claimed
US-12569439-B2 Bottom-up assembly of synthetic extracellular vesicles MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2026-03-10 US disclosed
US-20250195688-A1 Multiplexed Analysis of Materials for Tissue Delivery GEORGIA TECH RESEARCH CORPORATION 2025-06-19 US disclosed
EP-3225112-B2 PHOTOSENSITISER DISPERSION AND USE OF THE SAME TRIOPTOTEC GMBH (DE) 2025-03-26 EP disclosed
US-12201696-B2 Multiplexed analysis of materials for tissue delivery GEORGIA TECH RESEARCH CORPORATION (US) 2025-01-21 US disclosed
EP-3704262-B1 MULTIPLEXED ANALYSIS OF MATERIALS FOR TISSUE DELIVERY GEORGIA TECH RES INST (US) 2024-03-20 EP disclosed
CN-109152358-B Photosensitizer dispersions and uses thereof 特里奥普托泰克有限公司 2023-07-07 CN disclosed
US-20230181466-A1 BOTTOM-UP ASSEMBLY OF SYNTHETIC EXTRACELLULAR VESICLES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-06-15 US disclosed
US-11633365-B2 Nucleic acid-containing lipid nanoparticle KYOWA KIRIN CO., LTD. (JP) 2023-04-25 US disclosed
US-20230038598-A1 MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED CARGO DELIVERY MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-02-09 US disclosed
US-7906147-B2 superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography NANOPROBES, INC. (US) 2011-03-15 US disclosed
US-20090281054-A1 COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES SEQUELLA, INC. 2009-11-12 US disclosed
US-20080089836-A1 superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography NANOPROBES, INC. (US) 2008-04-17 US disclosed
US-6613352-B2 Administration a low-rigidity liposomal formulation comprising anionic and neutral phospholipids, free of cholesterol and an active agent for preventing or diagnosis of a nonbacterial microbal infection in human UNIVERSITE DE MONTREAL (CA) 2003-09-02 US disclosed
US-20010006660-A1 LOW-RIGIDITY LIPOSOMAL FORMULATION UNIVERSITE DE MONTREAL (CA) 2001-07-05 US disclosed
US-5696097-A Antineoplastic 5'-diacylglycerylphosphatidyl-2-deoxy-2'-methylenylcytidines and method of making YAMASA CORPORATION (JP) 1997-12-09 US disclosed
EP-0690068-A1 NOVEL 2'-METHYLIDENENUCLEOTIDE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND PHARMACEUTICAL USE THEREOF Matsuda, Akira (JP) 1996-01-03 EP disclosed
EP-0122151-B1 PRODUCTION OF PRIMARY OR SECONDARY ALCOHOL DERIVATIVES OF PHOSPHOLIPIDS BY THE ENZYMATIC TECHNIQUE MEITO SANGYO KABUSHIKI KAISHA (JP) 1989-02-15 EP disclosed
US-4783402-A Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique MEITO SANGYO KABUSHIKI KAISHA (JP) 1988-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230038598-A1 MICROFLUIDIC PRODUCTION OF BIOFUNCTIONALIZED GIANT UNILAMELLAR VESICLES FOR TARGETED CARGO DELIVERY PCNA, BOD1L1, SARS1 AKT1 4173/4885LMNA 1040/4885ALDH1A1 3690/4885
US-11633365-B2 Nucleic acid-containing lipid nanoparticle LIPA, LIPC, PNLIP AKT1 4007/4885LMNA 570/4885ALDH1A1 354/4885
US-20090281054-A1 COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES TTPA, PHOSPHO1, CAPG AKT1 2508/4885LMNA 180/4885ALDH1A1 2628/4885
US-20080089836-A1 superparamagnetic nanoparticles of iron coated with bilayer of molecules:(a) layer of oleic acid in direct contact with the iron particles; (b) a layer of Tween\"; bilayer of surface binding molecules and amphiphatic molecules; self-assembles; solubilizing; reducing toxicity; gold in MRI and tomography TFRC, FABP1, SCARB1 AKT1 1049/4885LMNA 2687/4885ALDH1A1 4468/4885
US-12569439-B2 Bottom-up assembly of synthetic extracellular vesicles EXOSC10, PLTP, EXOSC9 AKT1 1390/4885LMNA 1414/4885ALDH1A1 4712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.